MAIA Biotechnology Announces Private Placement of Approximately $669,500
May 27 2025 - 4:30PM
Business Wire
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the
“Company”), a clinical-stage biopharmaceutical company developing
targeted immunotherapies for cancer, today announced that it has
entered into definitive agreements for the purchase and sale of an
aggregate of 446,332 shares of common stock at a purchase price of
$1.50 per share, in a private placement to accredited investors and
a Company director. Each share of common stock is being offered
together with a warrant to purchase one share of common stock at an
exercise price of $1.71 per share, which price represents the
greater of the book or market value of the stock on the date the
definitive agreements were executed (subject to customary
adjustments as set forth in the warrants). The warrants are
exercisable commencing six-months following issuance and have a
term of five years from the initial issuance date. The securities
being sold to the Company director participating in the offering
are being issued pursuant to the Company’s 2021 Equity Incentive
Plan. The private placement is expected to close on or about May
29, 2025, subject to the satisfaction of customary closing
conditions.
The gross proceeds from the offering are expected to be
approximately $669,500, prior to offering expenses payable by the
Company. The Company intends to use the net proceeds from the
offering for to fund the execution of Step 1 of Part C of the Phase
II trial THIO -101 and for working capital.
The securities described above are being offered in a private
placement under Section 4(a)(2) of the Securities Act of 1933, as
amended (the “Securities Act”), and/or Regulation D promulgated
thereunder and, along with the shares of common stock underlying
the warrants, have not been registered under the Securities Act, or
applicable state securities laws. Accordingly, the warrants and
underlying shares of common stock may not be offered or sold in the
United States except pursuant to an effective registration
statement or an applicable exemption from the registration
requirements of the Securities Act and such applicable state
securities laws.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on
the development and commercialization of potential first-in-class
drugs with novel mechanisms of action that are intended to
meaningfully improve and extend the lives of people with cancer.
Our lead program is ateganosine (THIO), a potential first-in-class
cancer telomere targeting agent in clinical development for the
treatment of NSCLC patients with telomerase-positive cancer cells.
For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of
historical facts contained in this press release, are
forward-looking statements. Forward-looking statements are subject
to known and unknown risks, uncertainties, and other factors that
may cause our or our industry’s actual results, levels or activity,
performance or achievements to be materially different from those
anticipated by such statements. The use of words such as “may,”
“might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,”
or “continue,” and other similar expressions are intended to
identify forward looking statements. However, the absence of these
words does not mean that statements are not forward-looking. For
example, all statements we make regarding (i) completion of the
private placement, (ii) the initiation, timing, cost, progress and
results of our preclinical and clinical studies and our research
and development programs, (iii) our ability to advance product
candidates into, and successfully complete, clinical studies, (iv)
the timing or likelihood of regulatory filings and approvals, (v)
our ability to develop, manufacture and commercialize our product
candidates and to improve the manufacturing process, (vi) the rate
and degree of market acceptance of our product candidates, (vii)
the size and growth potential of the markets for our product
candidates and our ability to serve those markets, and (viii) our
expectations regarding our ability to obtain and maintain
intellectual property protection for our product candidates, are
forward looking. All forward-looking statements are based on
current estimates, assumptions and expectations by our management
that, although we believe to be reasonable, are inherently
uncertain. Any forward-looking statement expressing an expectation
or belief as to future events is expressed in good faith and
believed to be reasonable at the time such forward-looking
statement is made. However, these statements are not guarantees of
future events and are subject to risks and uncertainties and other
factors beyond our control that may cause actual results to differ
materially from those expressed in any forward-looking statement.
Any forward-looking statement speaks only as of the date on which
it was made. We undertake no obligation to publicly update or
revise any forward-looking statement, whether as a result of new
information, future events or otherwise, except as required by law.
In this release, unless the context requires otherwise, “MAIA,”
“Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc.
and its subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250527845229/en/
Investor Relations Contact +1 (872) 270-3518
ir@maiabiotech.com
Maia Biotechnology (AMEX:MAIA)
Historical Stock Chart
From Jun 2025 to Jul 2025
Maia Biotechnology (AMEX:MAIA)
Historical Stock Chart
From Jul 2024 to Jul 2025